Establishing Meaningful Change Thresholds for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL-specific Module Domain Scores: An Analysis Based on the TRANSCEND CLL 004 Study in Patients with Relapsed Or...

Overview

Journal EJHaem

Specialty Hematology

Date 2024 Dec 18

PMID 39691275

Authors

Laurie Eliason

Fatoumata Fofana

Lin Wang

Peter A Riedell

Shien Guo

Affiliations

Soon will be listed here.

Abstract

Introduction: The study aimed to establish meaningful thresholds at patient and group levels for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL-specific module (EORTC QLQ-CLL17) domain scores in adults with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL).

Material And Methods: Data for the analysis were from the TRANSCEND CLL 004 study (NCT03331198). EORTC QLQ-CLL17 and selected anchor measures were assessed at baseline and multiple postbaseline visits up to 24 months after treatment initiation. Thresholds for each of the three EORTC QLQ-CLL17 domains were triangulated based on estimates derived from anchor- and distribution-based analyses, in accordance with published guidance.

Results: The analysis included 62 patients with 240 observations across visits. Meaningful change thresholds for improvement and deterioration, respectively, at the patient level were determined to be -11/+11 for symptom burden, -16/+16 for physical condition/fatigue and -16/+13 for worries/fears on health and functioning. The meaningful change thresholds for improvement and deterioration at the group level mostly ranged between 0.3 and 0.5 of the standard deviation of baseline domain scores.

Conclusions: These thresholds, based on EORTC QLQ-CLL17 domain scores, could help identify patients with meaningful changes in HRQOL and interpret treatment effects in future studies of treatments for adults with R/R CLL.

References

Musoro J, Sodergren S, Coens C, Pochesci A, Terada M, King M . Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. Colorectal Dis. 2020; 22(12):2278-2287. DOI: 10.1111/codi.15295. View

Holtzer-Goor K, Schaafsma M, Joosten P, Posthuma E, Wittebol S, Huijgens P . Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015; 24(12):2895-906. PMC: 4615661. DOI: 10.1007/s11136-015-1039-y. View

Musoro J, Coens C, Greimel E, King M, Sprangers M, Nordin A . Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecol Oncol. 2020; 159(2):515-521. DOI: 10.1016/j.ygyno.2020.09.007. View

Eichhorst B, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M . Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol. 2007; 25(13):1722-31. DOI: 10.1200/JCO.2006.05.6929. View

Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C . Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere. 2020; 4(1):e336. PMC: 7000471. DOI: 10.1097/HS9.0000000000000336. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

van den Broek E, Oerlemans S, Nijziel M, Posthuma E, Coebergh J, van de Poll-Franse L . Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. Ann Hematol. 2014; 94(1):45-56. DOI: 10.1007/s00277-014-2161-6. View

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S . International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res. 2017; 27(2):333-345. PMC: 5846994. DOI: 10.1007/s11136-017-1718-y. View

Oerlemans S, Efficace F, Kieffer J, Kyriakou C, Xochelli A, Levedahl K . International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. Br J Haematol. 2022; 197(4):431-441. DOI: 10.1111/bjh.18072. View

10.

Molica S . Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma. 2005; 46(12):1709-14. DOI: 10.1080/10428190500244183. View

11.

Hallek M . Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94(11):1266-1287. DOI: 10.1002/ajh.25595. View

12.

Siddiqi T, Maloney D, Kenderian S, Brander D, Dorritie K, Soumerai J . Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023; 402(10402):641-654. PMC: 11753452. DOI: 10.1016/S0140-6736(23)01052-8. View

13.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

14.

Musoro J, Coens C, Sprangers M, Brandberg Y, Groenvold M, Flechtner H . Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer. 2023; 188:171-182. DOI: 10.1016/j.ejca.2023.04.027. View

15.

Musoro J, Coens C, Fiteni F, Katarzyna P, Cardoso F, Russell N . Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer. JNCI Cancer Spectr. 2020; 3(3):pkz037. PMC: 7050000. DOI: 10.1093/jncics/pkz037. View

16.

Cocks K, King M, Velikova G, Martyn St-James M, Fayers P, Brown J . Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2010; 29(1):89-96. DOI: 10.1200/JCO.2010.28.0107. View

17.

Hallek M, Al-Sawaf O . Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021; 96(12):1679-1705. DOI: 10.1002/ajh.26367. View

18.

Rai K, Jain P . Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol. 2015; 91(3):330-40. DOI: 10.1002/ajh.24282. View

19.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

20.

Waweru C, Kaur S, Sharma S, Mishra N . Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020; 36(9):1481-1495. DOI: 10.1080/03007995.2020.1784120. View